Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.
about
Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistanceResistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical ImplicationsEra of direct acting antivirals in chronic hepatitis C: Who will benefit?HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral TherapyInhibitors of the Hepatitis C Virus Polymerase; Mode of Action and ResistanceMouse Systems to Model Hepatitis C Virus Treatment and Associated ResistanceState of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and ImmunizationHepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus controlRapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader AssayHigh-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methodsGlobal prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome dataNaturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China.Deconvoluting the composition of low-frequency hepatitis C viral quasispecies: comparison of genotypes and NS3 resistance-associated variants between HCV/HIV coinfected hemophiliacs and HCV monoinfected patients in Japan.Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia.Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.Analysis of Naturally Occurring Resistant Mutations to Hepatitis C Virus NS3 Protease Inhibitors: A Preliminary Study in South of Iran.Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C.High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study.New treatments for chronic hepatitis C: an overview for paediatricians.Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals.Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment.Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.Assessment of a Novel Automatic Real-Time PCR Assay on the Cobas 4800 Analyzer as a Screening Platform for Hepatitis C Virus Genotyping in Clinical Practice: Comparison with Massive Sequencing.Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection.Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis CUse of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study.Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients.Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China.Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil.Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs.Analysis of naturally occurring resistance-associated variants to NS3/4A protein inhibitors, NS5A protein inhibitors and NS5B polymerase inhibitors in patients with chronic hepatitis C.Prevalence of NS5B resistance-associated variants in treatment-naïve Asian patients with chronic hepatitis C.Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy.Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem?Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected PatientsPrevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus
P2860
Q26740219-82A99E6E-5041-449A-9F57-F12906B0CE9AQ26777408-6993EE6C-3702-4ED4-8937-AC017CCF94D5Q26777506-0F76B69B-33B3-4CE8-AA73-655CA3378C9FQ26782405-FDECA868-89C0-4DEA-BB9B-86DB8EBB19CDQ26783056-023D1024-F196-4A9A-AA97-FE7396A77C39Q27469038-92BD9E68-D9A3-4B63-92EE-38CA78E9B992Q28079102-7951523E-8631-4BDD-BCF6-D622B021CDD4Q28082128-B2E2E17F-D979-4C9E-BD3A-60E740B4C4CAQ28548426-7C1335C5-C1FF-4276-93F5-406E76B91A34Q28652352-FC3B8AFF-E2C9-4FD7-A3F4-11D28D79CAA8Q31042796-CDDE4C36-618D-4E4F-8E7B-78908DAA703AQ33672648-BA5C2AED-F991-4624-9FCC-3B1A5B6264B8Q35154587-C08DE6AC-44A0-42B5-8770-676835C3F001Q35735285-86DA746C-6C23-47CC-AF9F-A9F30467ABA7Q35917596-89899C21-F259-4EF9-8CB1-DD8571AC7BB2Q36100521-CF193A67-6AB5-4499-B263-6152528D5403Q36182240-FAF72A24-4201-427F-A600-5EBA34C2DBDAQ36278496-177F7F87-F9D6-46E7-B947-27C35EF75098Q36292486-8541EE48-5BE0-4586-A171-0CD685B27D8DQ36651317-FA8745B8-A737-4256-B149-763D4569A096Q38282842-67ED7CE8-A0EC-4AE6-8A18-5C033F5FE919Q38779980-6473D05E-716A-4456-A2BE-FF0A89B02212Q38888859-34739BBC-814B-4FC2-9059-28DE36DEE20EQ39020651-79753927-EEB3-4F83-9CCC-8BC40F454728Q40419604-42B9B329-0777-487C-BB8F-EB59B09BF185Q40784280-3E7C16BD-2252-4E3B-A8E6-C75562BB6032Q41521289-CE5B108A-9F9C-4D68-B69F-5FFAD91F99E8Q42183060-0A499B55-9999-4817-B18F-4C4E35227EEEQ44104489-662D9D50-F3E6-41FA-A100-AA92CD936129Q45324124-8EE47980-BEC8-406F-8B7F-D9879C532A95Q45324912-3DDE3FDB-9643-4B81-80BF-24E37E4363A6Q47121746-DEE7FA1B-EA17-4D86-80B9-747D2EE1142AQ47314419-8A833322-F51C-4098-A9AE-FE370673F5C0Q47397635-3A29DA75-839D-4EFD-937B-2EE86A4A41AFQ55379857-6B4704BE-95C5-449A-93C4-325246DAF0FCQ57491238-AADFF0AE-C8D8-4B7F-9683-1CD9CAC9B999Q58780610-BAA157A2-C40A-483F-A123-8CB0DF8901F0Q59126211-1D969ECE-6A3E-4288-A877-C4D73D1F789B
P2860
Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Naturally occurring resistance ...... DAA treatment-naïve patients.
@en
Naturally occurring resistance ...... DAA treatment-naïve patients.
@nl
type
label
Naturally occurring resistance ...... DAA treatment-naïve patients.
@en
Naturally occurring resistance ...... DAA treatment-naïve patients.
@nl
prefLabel
Naturally occurring resistance ...... DAA treatment-naïve patients.
@en
Naturally occurring resistance ...... DAA treatment-naïve patients.
@nl
P2093
P2860
P50
P356
P1433
P1476
Naturally occurring resistance ...... DAA treatment-naïve patients.
@en
P2093
Giorgio Barbarini
Loretta Fiorina
Roberto Gulminetti
Stefano Novati
P2860
P356
10.1186/1743-422X-10-355
P577
2013-12-17T00:00:00Z